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Abstract
Type I and type II classes of interferons (IFNs) signal through the JAK/STAT1 pathway and are known to be impor-
tant in adaptive and innate immune responses and in protection against tumors. Although STAT1 is widely con-
sidered a tumor suppressor, it remains unclear, however, if this function occurs in tumor cells (cell autonomous) or
if STAT1 acts primarily through immune cells. Here, the question of whether STAT1 has a cell autonomous role in
mammary tumor formation was addressed in a mouse model of ERBB2/neu–induced breast cancer in the absence
and presence of STAT1. For this purpose, mice that carry floxed Stat1 alleles, which permit cell-specific removal of
STAT1, were generated. To induce tumors only in mammary cells lacking STAT1, Stat1 floxed mice were crossed
with transgenic mice that express cre recombinase and the neu oncogene under the mouse mammary tumor virus
LTR (Stat1fl/fl NIC). Stat1 was effectively deleted in mammary epithelium of virgin Stat1fl/fl NIC females. Time-to-
tumor onset was significantly shorter in Stat1fl/fl NIC females than in WT NIC (Wilcoxon rank sum test, P = .02).
The median time-to-tumor onset in the Stat1fl/fl NIC mice was 49.4 weeks, whereas it was 62.4 weeks in the WT
NIC mice. These results suggest that STAT1 in mammary epithelial cells may play a role in suppressing tumori-
genesis. The Stat1 floxed allele described in this study is also a unique resource to determine the cellular targets of
IFNs and STAT1 action, which should aid our understanding and appreciation of these pathways.
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Introduction
Protection against tumors is critically dependent on the host immune
response [1]. Interferons (IFNs) are cytokines classified as type I
(IFNα, β, and others) and type II (IFNγ) that play an integral role
in the immune response to pathogens and tumors. IFNs are known
to be of central importance in tumor clearance; however, the mech-
anism of their action is unclear [1]. STAT1 is a member of the sig-
nal transducers and activators of transcription (STAT) family of
cytokine-inducible transcription factors. STATs become active tran-
scription factors after cytokine activation of a cytokine receptor com-
plex. They are tyrosine phosphorylated by receptor–associated janus
kinases ( JAKs), leading to their dimerization and translocation to the
nucleus. STAT1 homodimers exclusively mediate IFNγ signaling,
and STAT1 forms a complex with STAT2 and IRF9 (the ISGF3
complex) to mediate type I IFN signaling [2]. As a necessary medi-
ator of IFN signaling, STAT1 has distinct roles in both the adaptive
and innate host immune response [3]. These functions were demon-
strated in whole animal Stat1 knockout mouse studies, which display
hypersensitivity to viral and bacterial infections [4,5]. Humans with
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loss-of-function mutations in STAT1 have been diagnosed with
Mendelian predisposition to mycobacterial diseases [6,7].
Evidence that STAT1 has tumor suppressor properties includes
studies in mouse models of STAT1 and IFNγ receptor deficiency.
Stat1 and IFNγ receptor null mice show increased incidence of spon-
taneous tumors when exposed to methylcholanthrene or bred into a
p53-deficient background [8]. Administered systemically, IFNα has
antitumor activity and it is used clinically as part of a chemotherapy
regimen to treat several forms of cancer [9–12]. In vitro, IFNs can
inhibit proliferation of tumor cells through STAT1 [13]. In addition,
STAT1 has been suggested to mediate the tumorigenic properties of
osteopontin in mammary epithelial tumor cells [14].
Whereas some studies have demonstrated a role of STAT1 as a tu-
mor suppressor, others have linked constitutive activation of STAT1
and/or an overexpression of IFN-related genes to breast cancers asso-
ciated with poor prognosis, and they have suggested that activated
STAT1 may confer resistance to radiation and adjuvant cancer therapy
[15,16]. In fact, a role for STAT1 in promotion of leukemia develop-
ment has been reported [17]. The difference between these studies
and those that suggest a tumor suppressor role for STAT1 may reflect
the cell autonomous versus cell nonautonomous roles of STAT1.
A complete understanding of the cellular targets of IFNs and the
cell autonomous and nonautonomous roles of STAT1 is lacking in
part because of the limitations of whole animal knockout models. To
determine IFN/STAT1 functions in individual cell types, transplan-
tation of STAT1 null cells into irradiated recipients, NOD severe
combined immunodeficient mice or RAG2−/−mice, may be done; how-
ever, because of the inherent manipulation of the immune system in
the hosts, this approach does not allow for a complete appreciation
of the role of STAT1 in the immune system. To address this issue, we
have developed a floxed Stat1 allele to enable tissue-specific dis-
ruption of STAT1 expression. Here we report the use of this tool
to identify the cell autonomous role of STAT1 in mammary tumor
formation using a mouse model of neu/ERBB2–induced breast can-
cer. ERBB2 is a receptor tyrosine kinase that can contribute to breast
cancer when mutated or abnormally expressed. Approximately 20%
to 30% of primary human breast cancers have an amplification of
the ERBB2 gene or overexpression of ERBB2 [18]. Our results indi-
cate that tissue-specific removal of STAT1 reduces the average latency
of Neu/ERBB2 tumors. The mouse Stat1 conditional allele intro-
duced in this study serves as a tool that enables the identification
of the role of STAT1 in mammary tumor formation independent
of the role of STAT1 in the immune system. This model should
be valuable for fully appreciating the role of STAT1 in different cell
types and in discriminating between immune and nonimmune func-
tions of IFN/STAT1 signaling.
Methods
Construction of Targeting Vector for Stat1 Locus
Loxp sites were inserted into Stat1 locus between −750 from the
transcriptional start site and flanking the first three exons including
exon 3, which is the first translated exon of Stat1. To execute this tar-
geting strategy, a plasmid target vector containing the pLoxp3neoTK
backbone with three polymerase chain reaction–amplified homology
regions from the Stat1 locus of 129SvEv mouse genomic DNA was
constructed. Electroporation of the targeting vector in 129SvEv ES
cells was completed by Ingenious Targeting Laboratories (ITL, Stony
Brook, NY). Screening for successfully targeted ES clones was done by
Southern blot analysis using SpeI digested DNA and a 500-bp probe
matching an outside region upstream of the 5′ homology arm. Of
44 clones screened, 2 were positive for the 7.7-kb fragment, indicating
a successfully targeted Stat1 locus. Microinjection of blastocysts and
breeding of chimeras was performed at ITL.
Animals
Stat1 floxed mice were crossed with mice containing the mouse
mammary tumor virus (MMTV)-neu-IRES-cre transgene described
previously [19]. Animals were housed on a 12-hour light–dark cycle
and maintained on standard rodent chow. All procedures were ap-
proved by the National Institute of Diabetes and Digestive and Kidney
Diseases animal care and use committee under National Institutes of
Health guidelines.
Histology
Mammary glands were dissected from animals after killing. Glands
were fixed in 4% formaldehyde, and paraffin sections were prepared
(Histoserv, Germantown, MD). Antigen unmasking was carried out
using a decloaking chamber (Biocare Medical, Concord, CA). For
staining, primary antibodies against E-cadherin (BD Biosciences,
San Jose, CA), STAT1 (no. SC346; Santa Cruz Biotechnology, Santa
Cruz, CA), and phospho-STAT1 (no. 9171; Cell Signaling Technol-
ogy, Danvers, MA) were used. Detection was performed using sec-
ondary antimouse and antirabbit immunoglobulin G fluorescent
antibodies (Invitrogen, Carlsbad, CA).
Western Blot
Protein was extracted from mammary tumors or cells using lysis
buffer containing 50 mM Tris pH 7.6, 150 mM NaCl, 1% Triton
X-100, 10% glycerol, 2 mM EDTA, 10 mM tetrasodium pyrophos-
phate, 50 mM sodium fluoride, and Complete Mini protease inhibitor
cocktail (Roche, Indianapolis, IN). Equal amounts of protein were sepa-
rated on a 4% to 12%NuPage gradient gel (Invitrogen) and transferred
to a polyvinylidine fluoride membrane (Invitrogen) and incubated
with antibodies against STAT1 (no. SC346; Santa Cruz Biotechnology)
and phospho-STAT1 Tyr. 701 (no. 9171; Cell Signaling Technology).
Membranes were probed overnight with primary antibodies and were
incubated the following day with for 1 hour with HRP-conjugated
secondary antibodies (GE Healthcare, Chalfont St Giles, UK). HRP
was detected using ECL from Thermo Fisher Scientific (Waltham,
MA) and was exposed on radiographs (GE Healthcare).
Isolating Primary Tumor Cell Lines
Tumors (approximately 300 mg) were minced into a paste with a
razor blade. The paste was transferred to a 50-ml tube and tumor
pieces were washed three times with 25 ml of Dulbecco’s modified
Eagle medium (DMEM)/F12 + 5% FBS by allowing cells to settle
5 minutes between washes. Pieces were transferred to a T75 flask
standing upright and disaggregated by using 8000 U of collagenase
(I-05516; Sigma, St Louis, MO)/40 ml of DMEM/F12 + 10% FBS
overnight at 37% without shaking and were pipetted repeatedly the
next morning. The mixture was washed five times with DMEM/
F12 + 5% FBS as before. Cells were plated in DMEM/F12 + 10%
FBS + L-glutamine + antibiotic/antimycotic (Invitrogen) + 0.3 μM
hydrocortisone (H-0135; Sigma) + 10 ng/ml apotransferrin (T-1428;
Sigma) + 5 μg/ml insulin (C-9881; Sigma) + 5 nM β-estradiol (E-2758;
Sigma) +heparin 4%×10−4 (StemCellTechnologies) + 4ng/ml epidermal
growth factor (Stem Cell Technologies).
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Statistical Analysis
We compared time-to-tumor onset among WT NIC and Stat1f l/f l
NIC mice using Kaplan-Meier curves, Wilcoxon rank sum, and log-
rank tests as calculated by PROCLIFETEST, SAS 9.1 (SAS, Cary, NC).
Results
To determine cell-specific roles of IFN/STAT1 signaling in breast can-
cer, Stat1 floxed mice were generated, which permitted the specific ab-
rogation of STAT1 in mammary epithelium. Loxp sites were inserted
by homologous recombination of a targeting vector in 129SvEv ES
cells. One loxp site is located 750 bp upstream of the transcriptional
start site and another flanks the first translated exon, a total distance
of 4.0 kb (Figure 1A). Southern blot analysis using SpeI digestion and
an external probe was used to confirm successful targeting of the Stat1
locus. The expected 7.7-kb fragment of a successfully targeted Stat1
locus was found in 2 of 44 neomycin-resistant mouse ES cell clones
(Figure 1B). Recombination of the loxp sites by cre-mediated recombi-
nation was expected to remove 4.0 kb of the Stat1 locus and abrogate
Stat1 expression (Figure 1C ). To test the ability of this Stat1 floxed al-
lele to be recombined by cre recombinase, targeted Stat1 floxed mice
were crossed with transgenic MMTV-neu-IRES-cre (NIC)–expressing
mice to generate Stat1 floxed NIC mice. Stat1 floxed NIC females
expressed cre recombinase and mediated recombination in the germ
line, similar to previously studied MMTV-cre–expressing mouse lines
[20], producing offspring containing a combination of alleles we
termed Stat1f l (5′ and middle loxp sites recombined), Stat1f l neo (origi-
nal unrecombined locus containing the neomycin resistance gene and
Figure 1. (A) Stat1 locus–targeting strategy. Targeting strategy used to introduce loxP sites into the Stat1 locus. Generation of the Stat1
floxed allele was accomplished by addition of loxp sites flanking a 4-kb region of the Stat1 gene approximately 750 bp upstream of the
transcription start site and just 3′ of the first translated exon. Gray boxes and dashed lines indicate regions in the Stat1 locus that un-
derwent homologous recombination. Bold arrows indicate loxP sites. Probe indicates position of probe used for Southern blot with SpeI
digestion. Taking advantage of the property that the NIC transgene expresses in germ line cells, an allele containing a deleted neomycin
cassette, but retaining two intact loxP sites, was selected (floxed allele). After cre-mediated recombination of the floxed allele, the first
two untranslated exons and first translated exon (noted by ATG) are removed, forming a null allele. Figure not necessarily to scale. (B)
Representative Southern blot demonstrating an untargeted (left) and targeted (right) Stat1 locus. (C) Diagram of floxneo allele (top), flox
allele (middle), and null allele (lower). (D) STAT1 protein expression in liver, mammary gland, spleen, and thymus harvested from Stat1+/+,
Stat1 flneo/fl, and Stat1 flneo/flneo mice. STAT1 protein is not detectable in the Stat1 flneo/flneo tissue but is observed in Stat1flneo/fl, indicating
that the 1.9-kb neomycin cassette was inserted into a critical Stat1 promoter region at −750 bp.
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containing three separate loxp sites), and null (3′ and 5′ loxp sites re-
combined; Figure 1C).
To test the ability of the f l neo and f l allele to produce STAT1 protein
in the absence of cre recombinase, liver, thymus, spleen, and mammary
gland tissues were removed from Stat1+/+, Stat1 f l neo/f l, and Stat1 f l neo/
f l neo. Unexpectedly, in each tissue, the Stat1 f l neo/f lmice produced only
approximately 50% of the STAT1 protein. In addition, Stat1 f l neo/f l neo
tissues were nearly devoid of STAT1 protein (Figure 1D). This result
indicates that the neomycin resistance gene present in the Stat1f l neo
allele disrupted the critical transcriptional regulatory elements in the
Stat1 gene. Because the Stat1f l allele missing neomycin expressed
STAT1 at expected levels, this allele was used for all subsequent con-
ditional knockout studies.
Stat1 Floxed Allele Can Be Deleted Efficiently
To test the ability of the recombined null allele to abrogate STAT1
protein expression, we crossed animals with a single copy of the null
allele to generate embryos homozygous for the null allele (Stat1−/−).
From these embryos, we isolated mouse embryonic fibroblasts (MEFs)
to assess the completeness of the STAT1 protein abrogation. Using
MEFs with one Stat1 f loxed allele and one WT allele (Stat1 f l/+) as
a control, Western blot analysis demonstrated that Stat1−/− MEFs
did not express any detectable STAT1 protein (Figure 2). Antibodies
directed against the STAT1 C-terminus were used to control for the
possibility that only an N-terminal–truncated product was produced.
Epithelium-Specific Role of STAT1 in Neu-Induced
Tumor Formation
To test if STAT1 signaling within mammary epithelium affects the
establishment of neu-induced mammary tumors, tumor occurrence
in Stat1f l /f l NIC mice and WT NIC mice was followed up for a pe-
riod of up to 97 weeks (Figure 3). The earliest onset of tumors was
similar in both groups, with mice from both groups developing tu-
mors by approximately 36 weeks. However, there was evidence that
time-to-tumor development was shorter for Stat1f l /f l NIC versus WT
NIC mice. The evidence was stronger for the early period than for
the later one (Wilcoxon rank sum test, P =.02) and somewhat weaker
for the overall period (log-rank test, P =.08). The median time-to-
tumor onset in the Stat1f l /f l NIC mice was 49.4 weeks, whereas it
was 62.4 weeks in the WT NIC mice (Figure 3). To monitor STAT1
levels inWTNICmammary tumors and the efficiency of the Stat1 f l /f l
NIC model to remove Stat1 in mammary tumors, immunohistochem-
ical (IHC) staining of STAT1 was performed. STAT1 was readily de-
tectable in WT NIC tumors but not in tumors from Stat1f l /f l NIC
mice. These results indicate that STAT1 was efficiently abrogated in
mammary tumors from Stat1f l /f l NIC mice and that STAT1 in the
mammary epithelium may have a suppressive role in the development
of mammary tumors. MMTV-NIC expression has previously been
shown to be mainly restricted to the mammary compartment, with
very weak expression in immune cells [19]. However, because STAT1
expression remains intact in immune cells, our results do not rule out
the importance of STAT1 in the immune system in protecting the host
against tumor formation.
To confirm that STAT1 is deleted efficiently in mammary epithe-
lium, mammary tissues from WT NIC and Stat1f l /f l NIC mice were
subjected to IHC analysis using the C-terminal STAT1 antibody or
phospho-STAT1 antibody (Figure 4). After an intraperitoneal IFNγ
Figure 2.Mouseembryo fibroblastswere isolated fromStat1 fl/+ and
Stat1−/− embryos. STAT1 and pSTAT1 protein expression was con-
firmed to be absent in Stat1−/−MEFs using C-terminal antibodies.
Figure 3. Analysis of tumor formation in Stat1fl/fl NIC and WT NIC mice over time. Kaplan-Meier cumulative tumor-free proportion (la-
beled as “Survival Function”) versus time in weeks in WT NIC (n = 21) and Stat1fl/fl NIC (n = 27) mice. Mice without tumor development
were censored and included in the analysis.
902 Cell Autonomous Role of STAT1 in Breast Cancer Klover et al. Neoplasia Vol. 12, No. 11, 2010
Figure 4. Expression of STAT1 protein in mammary epithelium from WT NIC and Stat1fl/fl NIC mice by IHC. STAT1 staining was used to
test for the absence of STAT1 in tumors from Stat1fl/fl NIC mice. (A) WT NIC mammary duct showing nuclear STAT1 staining (pinkish
color, indicated by white arrows). (B) A complete lack of STAT1 expression is observed in Stat1fl/fl NIC mice. Non–tumor-containing
epithelium from approximately 1 year-old tumor-bearing mice is shown.
Figure 5. Expression of STAT1 inWT NIC and Stat1fl/fl NICmammary tumors and cultured primary tumor cells. (A, B) STAT1 staining (red
color) of WT (A) and Stat1fl/fl NIC (B) tumors. White arrow indicates STAT1 staining. (C, D) pSTAT1 staining of WT (C) and Stat1fl/fl NIC (D)
tumors. Nuclear pSTAT1 staining (pinkish color) is observed in WT NIC tumors near blood vessels after IFNγ injection (indicated by white
arrow). (E) Western blot analysis demonstrating the complete absence of STAT1 in Stat1fl/fl NIC tumor cells.
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injection before harvesting tissues, nuclear STAT1 was visible in WT
NIC but not Stat1f l /fl NIC mammary epithelium. These results con-
firmed that Stat1 can be efficiently deleted from cells expressing cre re-
combinase and provide a means to test the tissue-specific role of STAT1
in mammary tumor formation.
STAT1 expression was assessed in mammary tumors fromWT NIC
and Stat1fl /f l NICmice to confirm that tumors were not the result of a
selection of unrecombined cells. Tumors from IFNγ-injectedWT NIC
and Stat1fl /f l NIC mice were analyzed by IHC staining for the pres-
ence of STAT1. WT NIC (Figure 5A) but not Stat1fl /f l NIC tumors
(Figure 5B) showed abundant STAT1 staining. Because the IFNγ did
not penetrate the tumor in the period (30 minutes) of treatment,
pSTAT1 staining was only seen near blood vessels of WT NIC tumors
(Figure 5C). No pSTAT1 staining was observed in Stat1fl /f l NIC tu-
mors (Figure 5D). In addition, Western blot analysis revealed that
STAT1 was undetectable in tumor cells isolated from Stat1fl /f l NIC
tumors (Figure 5E).
To confirm that the loss of STAT1 in mammary epithelium did not
result in abnormal mammary development or cause tumors, Stat1f l /f l
mice were crossed with MMTV-cre and WAP-cre mice [20]. Parous
Stat1f l /f l MMTV-cre females lactated normally, indicating that loss
of STAT1 did not impair mammary function (not shown). Whole
mounts of parous 15-month-old Stat1f l /f l WAP-cre females demon-
strated that the lack of STAT1 did not affect the normal mammary
architecture or lead to hyperplasia (Figure 6).
Discussion
The goal of the current study was to generate a mouse model that will
be useful in determining cell autonomous STAT1 actions in mammary
tumor formation. In pursuit of this goal, we have generated a condi-
tional Stat1 allele in mice that can efficiently remove Stat1 in various
cell types in the presence of cre recombinase controlled by a tissue-
specific promoter. Generation of the Stat1 floxed allele was accom-
plished by addition of loxp sites flanking a 4-kb region of the Stat1
gene approximately 750 bp upstream of the transcription start site
and just 3′ of the first translated exon. Surprisingly, addition of the
1.9-kb neo cassette resulted in near-complete disruption of STAT1
expression, indicating a previously unreported vital promoter region
at −750 bp. For conditional studies, this challenge was overcome by
obtaining mice with the neomycin cassette removed, which restored
expression of STAT1. In these mice, only after cre-mediated recombi-
nation and disruption of this 4-kb region did loss of STAT1 protein
expression occur as detected by a C-terminus–specific STAT1 antibody.
Of particular interest in this study was identifying if STAT1 signal-
ing independent of the immune system has a role in tumor suppres-
sion. STAT1 has been primarily considered a tumor suppressor protein
because of the substantial increase in tumor susceptibility of STAT1
null mice to various tumor-causing insults [8]. STAT1-deficient mice
are more prone to chemically induced tumors, as well as spontaneous
tumors induced as a result of a p53 mutation. However, lack of STAT1
activity does not always enhance tumor formation in the presence of
an oncogenic stimulus [15,17].
Using mice with an oncogene (neu) expressed under the same pro-
moter as cre recombinase, we were able to test the hypothesis that
STAT1 has a tumor suppressor role in mammary epithelium. The lack
of STAT1 did reduce the median time onset of mammary tumors in
neu-expressing mammary epithelium, suggesting a tumor-suppressing
action of STAT1 in these cells. Although this study does not exclude a
tumor-suppressing action of STAT1 through immunosurveillance, it
Figure 6.Whole mounts of mammary tissue from Stat1fl/fl WAP-cre and controls showing similar mammary development and no sign of
hyperplasia. (A) Stat1fl/fl nonparous. (B) Stat1 fl/fl WAP-Cre nonparous. (C) Stat1fl/fl parous. (D) Stat1fl/fl WAP-Cre parous. Arrows are
present to indicate ductal structures, and white arrowheads point to lymph nodes.
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suggests that STAT1 can play a role in mammary epithelium and de-
lays tumor occurrence.
In summary, we have developed a floxed Stat1 allele that should be a
valuable tool for discriminating the cell-specific roles of STAT1 in
mice. The current study suggests that STAT1 plays a suppressive role
in ERBB2/neu induced breast cancer. We anticipate the Stat1 floxed
mice will provide many other insights into the cell-specific roles of IFN
and STAT1 signaling not previously appreciated.
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